Convalescent Serum in Prophylaxis of Measles

Nabarro, David; Signy, A. Gordon

doi:10.1136/bmj.1.3652.12

Cited by 6 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During this outbreak, 26 convalescent donors donated 201 plasma units, and samples with EBOV antibody titers < 1:64 were selected for use. Even though CP was found to contain microfilaria, this did not affect processing [ 117 ]. This plasma was also stored for subsequent emergencies [ 102 ].…”

Section: Convalescent Plasma Therapy (Cpt)mentioning

confidence: 99%

The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections

Moubarak

Kasozi

Hetta

et al. 2021

Life

View full text Add to dashboard Cite

Novel therapies for the treatment of COVID-19 are continuing to emerge as the SARS-Cov-2 pandemic progresses. PCR remains the standard benchmark for initial diagnosis of COVID-19 infection, while advances in immunological profiling are guiding clinical treatment. The SARS-Cov-2 virus has undergone multiple mutations since its emergence in 2019, resulting in changes in virulence that have impacted on disease severity globally. The emergence of more virulent variants of SARS-Cov-2 remains challenging for effective disease control during this pandemic. Major variants identified to date include B.1.1.7, B.1.351; P.1; B.1.617.2; B.1.427; P.2; P.3; B.1.525; and C.37. Globally, large unvaccinated populations increase the risk of more and more variants arising. With successive waves of COVID-19 emerging, strategies that mitigate against community transmission need to be implemented, including increased vaccination coverage. For treatment, convalescent plasma therapy, successfully deployed during recent Ebola outbreaks and for H1N1 influenza, can increase survival rates and improve host responses to viral challenge. Convalescent plasma is rich with cytokines (IL-1β, IL-2, IL-6, IL-17, and IL-8), CCL2, and TNFα, neutralizing antibodies, and clotting factors essential for the management of SARS-CoV-2 infection. Clinical trials can inform and guide treatment policy, leading to mainstream adoption of convalescent therapy. This review examines the limited number of clinical trials published, to date that have deployed this therapy and explores clinical trials in progress for the treatment of COVID-19.

show abstract

Section: Convalescent Plasma Therapy (Cpt)mentioning

confidence: 99%

The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections

Moubarak

Kasozi

Hetta

et al. 2021

Life

View full text Add to dashboard Cite

show abstract

“…In addition, animal models of influenza pneumonia have also shown satisfactory response of convalescent serum [20][21][22][23][24][25][26][27][28][29][30]. Other viral infections [31][32][33] such as Influenza [34], mumps [35], Herpes zoster [36], Poliomyelitis [37], and measles were also treated effectively [29,38]. However, in some of those early clinical examples, whole blood was transformed into serum by allowing it to clot, specifically known for treatment of measles [29].…”

Section: Advancements In Convalescent Blood or Plasma Therapy Since 1890mentioning

confidence: 99%

Convalescent Plasma Therapy and its Century-Old Untapped Potential for COVID-19

2020

View full text Add to dashboard Cite

Background: The COVID-19 virus, in terms of pathogenesis and disease spectrum, resembles its predecessor viral strains which caused outbreaks of SARS and MERs. Due to unavailability of approved treatment protocols, healthcare workers initiated treatment of COVID-19 patients with convalescent plasma therapy. Objective: To appraise similarities between the three Coronaviruses and deduce the effectiveness of CP therapy based on exploration of its efficacy in the SARS and MERS outbreaks. Analysis: A narrative review of case reports, randomised controlled trials and meta-analysis studies, on use of CP therapy in SARs and MERS, was conducted. Studies evaluated for the purpose of this review were added through search engines of PubMed Central and Google Scholar. Results: We concluded that CP therapy had been able to play pivotal roles in treating critically-ill SARS and MERS patients. The risks of unintended immunological responses among other factors, hindering CP Therapy’s approval from drug administration authorities, were weighed against favourable chanisms, such as hypercoagulability, that support its use in COVID-19 patients. Conclusion: Findings collected from these studies steered our path to theorize the possibility of reducing mortality with convalescent plasma therapy and support our rallying efforts for enlisting this in the official treatment protocol of COVID-19. Doi: 10.28991/SciMedJ-2020-0204-6 Full Text: PDF

show abstract

“…[20][21][22][23][24][25][26][27][28][29][30] In addition, animal models of influenza pneumonia have also shown satisfactory response of convalescent serum. [31][32][33] Other viral infections such as Influenza 34 , mumps 35 , Herpes zoster 36 , Poliomyelitis 37 , and measles 27,38 were also treated effectively. However, in some of those early clinical examples, whole blood was transformed into serum by allowing it to clot, specifically known for treatment of measles.…”

Section: Advancements In Convalescent Blood or Plasma Therapy Since 1890mentioning

confidence: 99%

Convalescent Plasma Therapy: A Century Old Technique for COVID-19 (Preprint)

Khan¹,

Ali²,

Lohana³

2020

Preprint

View full text Add to dashboard Cite

UNSTRUCTURED It has been proved that the current COVID-19 pandemic can be loosely bound to its predecessor outbreaks i.e. SARS and MERS. No vaccine or approved treatment is available for either coronavirus. At present, COVID-19 has infected 2,436,743 people in over 200 countries with unprecedented transmission rate. Healthcare workers in China initiated treatment of clinically worsening COVID-19 patients with a traditional method of passive immunity i.e. transfusion of plasma recovered from COVID-19 recuperated patients. According to available medical data, this technique is routinely favored by the World Health Organization (WHO) and has been in use since 1890 for combatting newly emerging infectious diseases, most commonly of a viral origin. Exploration of studies carried out on Convalescent Plasma and its effectiveness in the past steered our path to theorize the possibility of reducing mortality with convalescent plasma therapy and put together reviewed evidence to support our rallying efforts for enlisting this in the official treatment protocol of COVID-19.

show abstract

Convalescent Serum in Prophylaxis of Measles

Cited by 6 publications

References 0 publications

The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections

The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections

Convalescent Plasma Therapy and its Century-Old Untapped Potential for COVID-19

Convalescent Plasma Therapy: A Century Old Technique for COVID-19 (Preprint)

Contact Info

Product

Resources

About